Recent News

• 04.14.2025 - Heart-2 Data Disclosure Conference Call
• 04.14.2025 - Heart-2 Data Disclosure Conference Call
• 04.14.2025 - Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
• 04.14.2025 - Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
• 04.11.2025 - Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
• 04.11.2025 - Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
• 04.04.2025 - Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 04.04.2025 - Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 03.24.2025 - Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
• 03.24.2025 - Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

Recent Filings

• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities